Actualización sobre los agentes terapéuticos en enfermedad de Behcet, una sistemática revisión sobre una patología compleja
Resumen
DOI: https://doi.org/10.53766/AcBio/2023.13.25.11
El síndrome de Behçet (SB) es una vasculitis multisistémica con afectación vascular variable que muestra una heterogeneidad significativa entre los pacientes en cuanto a las manifestaciones clínicas y el curso de la enfermedad. La elección del tratamiento y la respuesta están influenciadas por esta heterogeneidad. Los objetivos principales de los tratamientos de SB son suprimir rápidamente las exacerbaciones inflamatorias y prevenir las recaídas para proteger las funciones de los órganos y proporcionar una buena calidad de vida. Además de la experiencia a largo plazo con los esteroides y los inmunosupresores tradicionales, los fármacos biológicos, especialmente los inhibidores del TNF, han adquirido una importancia creciente en el tratamiento del SB a lo largo de los años. En esta revisión, nuestro objetivo fue dar una visión general de los estudios con fármacos convencionales y biológicos con eficacia comprobada en el tratamiento de SB.
Recibido: 31/01/2023
Aceptado: 14/2/2023
Palabras clave
Texto completo:
PDFReferencias
Yazici H, Seyahi E, Hatemi G, Yazici Y. Behcet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14(2):119. doi: 10.1038/nrrheum.2018.3 [PubMed] [CrossRef] [Google Scholar]
Mendoza-Pinto C, Garcia-Carrasco M, Jimenez-Hernandez M, et al. Etiopathogenesis of Behcet’s disease. Autoimmun Rev. 2010;9(4):241–245. doi: 10.1016/j.autrev.2009.10.005 [PubMed] [CrossRef] [Google Scholar]
Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behcet’s syndrome. Ann Rheum Dis. 2018;77(6):808–818. doi: 10.1136/annrheumdis-2018-213225 [PubMed] [CrossRef] [Google Scholar]
OzUGler Y, Leccese P, Christensen R, et al. Management of major organ involvement of Behcet’s syndrome: a systematic review for update of the EULAR recommendations. Rheumatology (Oxford). 2018;57(12):2200–2212. doi: 10.1093/rheumatology/key242 [PubMed] [CrossRef] [Google Scholar]
Leccese P, OzUGler Y, Christensen R, et al. Management of skin, mucosa and joint involvement of Behcet’s syndrome: a systematic review for update of the EULAR recommendations for the management of Behcet’s syndrome. Semin Arthritis Rheum. 2019;48(4):752–762. doi: 10.1016/j.semarthrit.2018.05.008 [PubMed] [CrossRef] [Google Scholar]
Aktulga E, Altac M, Muftuoglu A, et al. A dUOble blind study of colchicine in Behcet’s disease. Haematologica. 1980;65(3):399–402. [PubMed] [Google Scholar]
Yurdakul S, Mat C, Tuzun Y, et al. A dUOble-blind trial of colchicine in Behcet’s syndrome. Arthritis Rheum. 2001;44(11):2686–2692. doi:10.1002/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H [PubMed] [CrossRef] [Google Scholar]
Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behcet’s disease: randomized, dUOble-blind, controlled crossover trial. Mod Rheumatol. 2009;19(5):542–549. doi: 10.3109/s10165-009-0200-2 [PubMed] [CrossRef] [Google Scholar]
Hamuryudan V, Hatemi G, Tascilar K, et al. Colchicine in Behcet syndrome: a long term survey of patients in a controlled trial. J Rheumatol. 2014;41(4):735–738. doi: 10.3899/jrheum.130847 [PubMed] [CrossRef] [Google Scholar]
Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet’s syndrome. N Engl J Med. 1990;322(5):281–285. doi: 10.1056/NEJM199002013220501 [PubMed] [CrossRef] [Google Scholar]
Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet’s syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40(4):769–774. doi: 10.1002/art.1780400425 [PubMed] [CrossRef] [Google Scholar]
Hatemi I, Esatoglu SN, Hatemi G, Erzin Y, Yazici H, Celik AF. Characteristics, treatment, and long-term UOtcome of gastrointestinal involvement in behcet’s syndrome: a strobe-compliant oSBervational study from a dedicated multidisciplinary center. Medicine (Baltimore). 2016;95(16):e3348. doi: 10.1097/MD.0000000000003348 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Jung YS, Cheon JH, Hong SP, Kim TI, Kim WH. Clinical UOtcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet’s disease. Inflamm Bowel Dis. 2012;18(4):750–757. doi: 10.1002/ibd.21757 [PubMed] [CrossRef] [Google Scholar]
OzUGler Y, Hatemi G, Cetinkaya F, et al. Clinical cUOrse of acute deep vein thrombosis of the legs in Behcet’s syndrome. Rheumatology (Oxford). 2020;59(4):799–806. [PubMed] [Google Scholar]
Girgin S, Yurumez S, Omma A, et al. Comparison of relapse rates in Behcet’s disease with venUOs involvement on different doses of azathioprine therapy, a retrospective oSBervational study. Int J Rheum Dis. 2021;24:562–566. doi: 10.1111/1756-185X.14075 [PubMed] [CrossRef] [Google Scholar]
Noel N, Bernard R, Wechsler B, et al. Long-term UOtcome of neuro-Behcet’s disease. Arthritis Rheumatol. 2014;66(5):1306–1314. doi: 10.1002/art.38351 [PubMed] [CrossRef] [Google Scholar]
Hamuryudan V, Ozyazgan Y, Fresko Y, Mat C, Yurdakul S, Yazici H. Interferon alfa combined with azathioprine for the uveitis of Behcet’s disease: an open study. Isr Med Assoc J. 2002;4(11 Suppl):928–930. [PubMed] [Google Scholar]
BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet’s syndrome. Transplant Proc. 1988;20(3 Suppl 4):136–143. [PubMed] [Google Scholar]
Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet’s syndrome: a single masked trial. Br J Ophthalmol. 1992;76(4):241–243. doi: 10.1136/bjo.76.4.241 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Masuda K, Nakajima A, Urayama A, Nakae K, KoUGre M, Inaba G. DUOble-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet’s disease. Lancet. 1989;1(8647):1093–1096. doi: 10.1016/S0140-6736(89)92381-7 [PubMed] [CrossRef] [Google Scholar]
Celiker H, Kazokoglu H, Direskeneli H. Conventional immunosuppressive therapy in severe Behcet’s Uveitis: the switch rate to the biological agents. BMC Ophthalmol. 2018;18(1):261. doi: 10.1186/s12886-018-0929-5 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Adler YD, Mansmann U, ZUObUOlis CC. Mycophenolate mofetil is ineffective in the treatment of mucocutaneUOs Adamantiades-Behcet’s disease. Dermatology. 2001;203(4):322–324. doi: 10.1159/000051781 [PubMed] [CrossRef] [Google Scholar]
Kose O, Simsek I, Pay S. Mycophenolate sodium in the treatment of mucocutaneUOs Behcet’s diseases. Int J Dermatol. 2011;50(7):895–896. doi: 10.1111/j.1365-4632.2010.04505.x [PubMed] [CrossRef] [Google Scholar]
Esatoglu SN, Cemre E, Hamuryudan V, et al. Mycophenolate mofetil in the treatment of major organ involvement of patients with behçet’s syndrome. Eur Congress Rheumatol. 2019;12–15(June):2019. [Google Scholar]
Shugaiv E, Tuzun E, Mutlu M, Kiyat-Atamer A, Kurtuncu M, Akman-Demir G. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behcet’s disease with parenchymal involvement: presentation of fUOr cases. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S64–67. [PubMed] [Google Scholar]
Hamuryudan V, Yurdakul S, Moral F, et al. Pulmonary arterial aneurysms in Behcet’s syndrome: a report of 24 cases. Br J Rheumatol. 1994;33(1):48–51. doi: 10.1093/rheumatology/33.1.48 [PubMed] [CrossRef] [Google Scholar]
Saba D, Saricaoglu H, Bayram AS, et al. Arterial lesions in Behcet’s disease. Vasa. 2003;32(2):75–81. doi: 10.1024/0301-1526.32.2.75 [PubMed] [CrossRef] [Google Scholar]
Yoon DL, Kim YJ, Koo SB, Kim YG, Lee CK, Yoo B. Neuro-behcet’s disease in SUOth Korea: clinical characteristics and treatment response. Int J Rheum Dis. 2014;17(4):453–458. doi: 10.1111/1756-185X.12265 [PubMed] [CrossRef] [Google Scholar]
UGrcan M, Esatoglu SN, Hamuryudan V, et al. Long term follow-up of Behcet’s syndrome patients treated with cyclophosphamide. Rheumatology (Oxford). 2020;59(9):2264–2271. doi: 10.1093/rheumatology/kez598 [PubMed] [CrossRef] [Google Scholar]
Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneUOs lesions of the Behcet syndrome. A randomized, dUOble-blind, placebo-controlled trial. Ann Intern Med. 1998;128(6):443–450. doi: 10.7326/0003-4819-128-6-199803150-00004 [PubMed] [CrossRef] [Google Scholar]
Hatemi I, Hatemi G, Pamuk ON, Erzin Y, Celik AF. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behcet’s syndrome refractory to the conventional treatment modalities: a case series and review of the literature. Clin Exp Rheumatol. 2015;33(6 Suppl 94):S129–137. [PubMed] [Google Scholar]
Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and dUOble-blind study. Arch Dermatol. 2002;138(4):467–471. doi: 10.1001/archderm.138.4.467 [PubMed] [CrossRef] [Google Scholar]
Kötter I, Vonthein R, Schoenfisch B, et al. Interferon alpha2a versus cyclosporin a for the treatment of severe ocular behcet’s disease – a prospective, randomised, single blind, national multicenter trial (INCYTOB). Annual Eur Congress Rheumatol. 2016. London, United Kingdom. [Google Scholar]
Lightman S, Taylor SR, Bunce C, et al. Pegylated interferon-alpha-2b reduces corticosteroid requirement in patients with Behcet’s disease with upreUGlation of circulating reUGlatory T cells and reduction of Th17. Ann Rheum Dis. 2015;74(6):1138–1144. doi: 10.1136/annrheumdis-2014-205571 [PubMed] [CrossRef] [Google Scholar]
Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet’s disease: a dUOble blind, placebo controlled study. J Rheumatol. 2005;32(1):98–105. [PubMed] [Google Scholar]
Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectiUOs uveitis. N Engl J Med. 2016;375(10):932–943. doi: 10.1056/NEJMoa1509852 [PubMed] [CrossRef] [Google Scholar]
NUGyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectiUOs uveitis controlled by corticosteroids (VISUAL II): a multicentre, dUOble-masked, randomised, placebo-controlled Phase 3 trial. Lancet. 2016;388(10050):1183–1192. doi: 10.1016/S0140-6736(16)31339-3 [PubMed] [CrossRef] [Google Scholar]
Hu Y, Huang Z, Yang S, Chen X, Su W, Liang D. Effectiveness and safety of anti-tumor necrosis factor-alpha agents treatment in behcets’ disease-associated uveitis: a systematic review and meta-analysis. Front Pharmacol. 2020;11:941. doi: 10.3389/fphar.2020.00941 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Atienza-Mateo B, Martin-Varillas JL, Calvo-Rio V, et al. Comparative study of infliximab versus adalimumab in refractory uveitis due to behcet’s disease: national multicenter study of 177 cases. Arthritis Rheumatol. 2019;71(12):2081–2089. doi: 10.1002/art.41026 [PubMed] [CrossRef] [Google Scholar]
Fabiani C, Vitale A, Rigante D, et al. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectiUOs intermediate uveitis, posterior uveitis, and panuveitis: a retrospective oSBervational study of 107 patients. Clin Rheumatol. 2019;38(2):407–415. doi: 10.1007/s10067-018-4228-6 [PubMed] [CrossRef] [Google Scholar]
Suzuki Y, Hagiwara T, Kobayashi M, Morita K, Shimamoto T, Hibi T. Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behcet’s disease: results from a large real-world oSBervational study. Intest Res. 2020. [PMC free article] [PubMed] [Google Scholar]
Lopalco G, Emmi G, Gentileschi S, et al. Certolizumab Pegol treatment in Behcet’s disease with different organ involvement: a multicenter retrospective oSBervational study. Mod Rheumatol. 2017;27(6):1031–1035. doi: 10.1080/14397595.2017.1285857 [PubMed] [CrossRef] [Google Scholar]
Vitale A, Emmi G, Lopalco G, et al. Long-term efficacy and safety of golimumab in the treatment of multirefractory Behcet’s disease. Clin Rheumatol. 2017;36(9):2063–2069. doi: 10.1007/s10067-017-3627-4 [PubMed] [CrossRef] [Google Scholar]
Aksoy A, Yazici A, Omma A, et al. Efficacy of TNFalpha inhibitors for refractory vascular Behcet’s disease: a multicenter oSBervational study of 27 patients and a review of the literature. Int J Rheum Dis. 2020;23(2):256–261. doi: 10.1111/1756-185X.13778 [PubMed] [CrossRef] [Google Scholar]
Li L, Liu JJ, Yu X, et al. [Efficacy and safety of anti-tumor necrosis factor alpha monoclonal antibodies in 16 patients with severe/refractory vasculo Behcet’s disease]. Zhonghua Nei Ke Za Zhi. 2020;59(4):303–308. Chinese. doi: 10.3760/cma.j.cn112138-20190730-00527 [PubMed] [CrossRef] [Google Scholar]
Desbois AC, Addimanda O, Bertrand A, et al. Efficacy of anti-tnfalpha in severe and refractory neuro-behcet disease: an oSBervational study. Medicine (Baltimore). 2016;95(23):e3550. doi: 10.1097/MD.0000000000003550 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Zeydan B, UyUGnoglu U, Saip S, et al. Infliximab is a plausible alternative for neurologic complications of Behcet disease. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e258. doi: 10.1212/NXI.0000000000000258 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Dincses E, Esatoglu SN, OzUGler Y, et al. Biosimilar infliximab for Behcet’s syndrome: a case series. Clin Exp Rheumatol. 2019;37 Suppl 121(6):111–115. [PubMed] [Google Scholar]
Cantini F, Niccoli L, Nannini C, Cassara E, KalUOdi O. Rapid loss of efficacy of biosimilar infliximab in three patients with Behcet’s disease after switching from infliximab originator. Eur J Rheumatol. 2017;4(4):288–290. doi: 10.5152/eurjrheum.2017.16112 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Lopalco G, Venerito V, Cantarini L, Emmi G, Prisco D, Iannone F. Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behcet’s disease. Intern Emerg Med. 2019;14(5):719–722. doi: 10.1007/s11739-018-1970-3 [PubMed] [CrossRef] [Google Scholar]
Esatoglu SN, Akkoc-Mustafayev FN, OzUGler Y, et al. Immunogenicity of infliximab among patients with behcet syndrome: a controlled study. Front Immunol. 2020;11:618973. doi:10.3389/fimmu.2020.618973 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
UGl A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin-1beta-reUGlating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis. 2012;71(4):563–566. doi: 10.1136/annrheumdis-2011-155143 [PubMed] [CrossRef] [Google Scholar]
Tugal-Tutkun IM, Kadayifcilar SM, Khairallah MM, et al. Safety and efficacy of gevokizumab in patients with behcet’s disease uveitis: results of an exploratory phase 2 study. Ocul Immunol Inflamm. 2017;25(1):62–70. doi: 10.3109/09273948.2015.1092558 [PubMed] [CrossRef] [Google Scholar]
Tugal-Tutkun I, Pavesio C, De CordUOe A, Bernard-Poenaru O, UGl A. Use of gevokizumab in patients with behcet’s disease uveitis: an international, randomized, dUOble-masked, placebo-controlled study and open-label extension study. Ocul Immunol Inflamm. 2018;26(7):1023–1033. doi: 10.1080/09273948.2017.1421233 [PubMed] [CrossRef] [Google Scholar]
Bettiol A, Silvestri E, Di Scala G, et al. The right place of interleukin-1 inhibitors in the treatment of Behcet’s syndrome: a systematic review. Rheumatol Int. 2019;39(6):971–990. doi: 10.1007/s00296-019-04259-y [PubMed] [CrossRef] [Google Scholar]
Akiyama M, Kaneko Y, Takeuchi T. Effectiveness of tocilizumab in Behcet’s disease: a systematic literature review. Semin Arthritis Rheum. 2020;50(4):797–804. doi: 10.1016/j.semarthrit.2020.05.017 [PubMed] [CrossRef] [Google Scholar]
Emmi G, Silvestri E, Squatrito D, Emmi L, Cantarini L, Prisco D. Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory Behcets disease. Semin Arthritis Rheum. 2016;46(1):e1–2. doi:10.1016/j.semarthrit.2016.03.006 [PubMed] [CrossRef] [Google Scholar]
Cantarini L, Lopalco G, Vitale A, et al. Paradoxical mucocutaneUOs flare in a case of Behcet’s disease treated with tocilizumab. Clin Rheumatol. 2015;34(6):1141–1143. doi: 10.1007/s10067-014-2589-z [PubMed] [CrossRef] [Google Scholar]
DiamantopUOlos AP, Hatemi G. Lack of efficacy of tocilizumab in mucocutaneUOs Behcet’s syndrome: report of two cases. Rheumatology (Oxford). 2013;52(10):1923–1924. doi: 10.1093/rheumatology/ket130 [PubMed] [CrossRef] [Google Scholar]
Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectiUOs uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777–787. doi: 10.1016/j.ophtha.2012.09.040 [PubMed] [CrossRef] [Google Scholar]
Di Scala G, Bettiol A, Cojan RD, Finocchi M, Silvestri E, Emmi G. Efficacy of the anti-IL 17 secukinumab in refractory Behcet’s syndrome: a preliminary study. J Autoimmun. 2019;97:108–113. doi: 10.1016/j.jaut.2018.09.002 [PubMed] [CrossRef] [Google Scholar]
Fagni F, Bettiol A, Talarico R, et al. Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behcet’s phenotype: a multicentre study. Ann Rheum Dis. 2020;79(8):1098–1104. doi: 10.1136/annrheumdis-2020-217108 [PubMed] [CrossRef] [Google Scholar]
Dincses E, Yurttas B, Esatoglu SN, Melikoglu M, Hamuryudan V, Seyahi E. Secukinumab induced Behcet’s syndrome: a report of two cases. Oxf Med Case Rep. 2019;2019(5):omz041. doi: 10.1093/omcr/omz041 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Calleja Algarra A, Aragon MiUGel R, Andres Lencina JJ, et al. Behcet’s-like disease during secukinumab treatment: new paradoxical reaction? J Dtsch Dermatol Ges. 2021;19(1):116–118. [PubMed] [Google Scholar]
Barrado-Solis N, Rodrigo-Nicolas B, De la Morena-barrio I, et al. Report of two cases of Behcet’s disease developed during treatment with secukinumab. J Eur Acad Dermatol Venereol. 2020;34(10):e587–e589. doi: 10.1111/jdv.16454 [PubMed] [CrossRef] [Google Scholar]
MirUOse A, Barete S, Monfort JB, et al. Ustekinumab for Behcet’s disease. J Autoimmun. 2017;82:41–46. doi: 10.1016/j.jaut.2017.05.002 [PubMed] [CrossRef] [Google Scholar]
MirUOse A, Barete S, Desbois AC, et al. Long-term UOtcome of ustekinumab therapy for behcet’s disease. Arthritis Rheumatol. 2019;71(10):1727–1732. doi: 10.1002/art.40912 [PubMed] [CrossRef] [Google Scholar]
Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behcet’s syndrome--a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510–1518. doi: 10.1056/NEJMoa1408684 [PubMed] [CrossRef] [Google Scholar]
Hatemi G, Mahr A, Ishigatsubo Y, et al. Trial of apremilast for oral ulcers in behcet’s syndrome. N Engl J Med. 2019;381(20):1918–1928. doi: 10.1056/NEJMoa1816594 [PubMed] [CrossRef] [Google Scholar]
Atienza-Mateo B, Martin-Varillas JL, Grana J, et al. Apremilast in refractory orogenital ulcers and other manifestations of Behcet’s disease. A national multicentre study of 51 cases in clinical practice. Clin Exp Rheumatol. 2020;38 Suppl 127(5):69–75. [PubMed] [Google Scholar]
Vieira M, Buffier S, Vautier M, et al. Apremilast in refractory behcet’s syndrome: a multicenter oSBervational study. Front Immunol. 2020;11:626792. doi: 10.3389/fimmu.2020.626792 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Liu J, HUO Y, Sun L, et al. A pilot study of tofacitinib for refractory Behcet’s syndrome. Ann Rheum Dis. 2020;79(11):1517–1520. doi: 10.1136/annrheumdis-2020-217307 [PubMed] [CrossRef] [Google Scholar]
Liu J, Zhao C, Zheng W. Response to: ‘Correspondence on ‘A pilot study of tofacitinib for refractory Behcet’s syndrome’’ by ZUO et al. Ann Rheum Dis. 2021. doi: 10.1136/annrheumdis-2020-219828 [PubMed] [CrossRef] [Google Scholar]
Tuzun H, Seyahi E, UGzelant G, et al. Surgical treatment of pulmonary complications in behcet’s syndrome. Semin Thorac Cardiovasc Surg. 2018;30(3):369–378. doi: 10.1053/j.semtcvs.2018.07.008 [PubMed] [CrossRef] [Google Scholar]
Esatoglu SN, Seyahi E, UUGrlu S, et al. Bronchial artery enlargement may be the cause of recurrent haemoptysis in Behcet’s syndrome patients with pulmonary artery involvement during follow-up. Clin Exp Rheumatol. 2016;34(6 Suppl 102):92–96. [PubMed] [Google Scholar]
Yildizeli SO, Yanartas M, Tas S, et al. UOtcomes of patients with behcet’s syndrome after pulmonary endarterectomy. Thorac Cardiovasc Surg. 2018;66(2):187–192. doi: 10.1055/s-0037-1604411 [PubMed] [CrossRef] [Google Scholar]
Dincses E, Esatoglu SN, Fresko I, Melikoglu M, Seyahi E. UOtcome of invasive procedures for venUOs thrombosis in Behcet’s syndrome: case series and systematic literature review. Clin Exp Rheumatol. 2019;37 Suppl 121(6):125–131. [PubMed] [Google Scholar]
Jung JY, Kim DY, Bang D. Leg ulcers in Behcet’s disease. Br J Dermatol. 2008;158(1):178–179. doi:10.1111/j.1365-2133.2007.08234.x [PubMed] [CrossRef] [Google Scholar]
Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Long-term clinical UOtcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol. 2012;46(5):e38–45. doi: 10.1097/MCG.0b013e3182431d56 [PubMed] [CrossRef] [Google Scholar]
Soysal T, Salihoglu A, Esatoglu SN, et al. Bone marrow transplantation for Behcet’s disease: a case report and systematic review of the literature. Rheumatology (Oxford). 2014;53(6):1136–1141. doi: 10.1093/rheumatology/ket479 [PubMed] [CrossRef] [Google Scholar]
Yilmaz U, Ar MC, Esatoglu SN, et al. How to treat myelodysplastic syndrome with clinical features resembling Behcet syndrome: a case-based systematic review. Ann Hematol. 2020;99(6):1193–1203. doi: 10.1007/s00277-020-03951-5 [PubMed] [CrossRef] [Google Scholar]
Hatemi G, Meara A, OzUGler Y, et al. The OMERACT core set of domains for UOtcome measures in behcet syndrome. Arthritis Care Res (Hoboken). 2020. doi: 10.1002/acr.24511 [PubMed] [CrossRef] [Google Scholar]
DOI: https://www.doi.org/10.53766/AcBio/Se encuentra actualmente indizada en: | |||
Todos los documentos publicados en esta revista se distribuyen bajo una
Licencia Creative Commons Atribución -No Comercial- Compartir Igual 4.0 Internacional.
Por lo que el envío, procesamiento y publicación de artículos en la revista es totalmente gratuito.